Tariff headlines are back in focus, and this time the pressure is squarely on import costs for U.S. consumers and businesses. With Virginia and other states pushing back against broad U.S. tariffs, investors are weighing what heavier trade frictions and higher prices could mean for different parts of the market. Domestic focused stocks that rely less on imported inputs can appear relatively insulated when trade tensions rise, while others may face higher cost pressure or sentiment swings. This article walks through 3 U.S. listed stocks exposed to these tariff developments and explains why they may be of interest now.

Privia Health Group (PRVA)

Overview: Privia Health Group is a U.S. based physician enablement company that helps doctors and health systems run more efficient primary and specialty care practices by providing technology, administration support, and value based care infrastructure, with a strong focus on seniors.

Operations: Privia generates about US$2.2b in revenue from Healthcare Facilities & Services, almost entirely within the United States.

Market Cap: US$3.4b

Privia Health Group operates in a tariff heavy backdrop, but its roughly US$2.2b in healthcare services revenue is almost entirely tied to U.S. patients rather than imported goods that could see costs rise. Investors are watching its push into new states such as New Jersey and its growing value based care footprint. Together, these initiatives support recurring fees and earnings momentum, even though net margins are still modest at around 1% and long term ROE is expected to be relatively low. The stock appears cheaper than many peers on a sales basis. However, recent insider selling and reliance on external borrowing suggest that the situation is complex, particularly with an upcoming Q2 earnings update on August 6, 2026 that could influence sentiment.

Privia Health Group’s push into new states, growing value based care and modest 1% margins raise a clear question: what is really priced in? Walk through the 3 key rewards and 1 important warning sign

Surgery Partners (SGRY)

Overview: Surgery Partners operates a large network of outpatient surgery centers and surgical hospitals across the United States, handling non emergency procedures across orthopedics and pain management, eye care, gastrointestinal care and general surgery, alongside supporting services such as anesthesia, diagnostic testing and physician practices.

Operations: Surgery Partners generates about US$3.3b in revenue from its Surgical Facilities and ancillary services, all within the United States.

Market Cap: US$2.1b

For investors looking at tariff resilient ideas, Surgery Partners stands out because its US$3.3b in revenue is tied to domestic surgical care rather than imports, while management says tariff exposure in procurement is limited and largely built into current guidance. The stock screens as heavily discounted on sales and intrinsic value estimates, yet the company is still reporting losses and relies entirely on external borrowing, so the path to margin repair and a return to profitability is central to the thesis. In addition, management’s focus on higher acuity procedures, cost containment and portfolio reshaping means Surgery Partners presents a mix of value, operational progress and execution risk that investors may wish to examine more closely.

Surgery Partners’ valuation discount and shift toward higher acuity procedures suggest that the headline losses may not tell the full story. See how the analysis report for Surgery Partners frames the potential upside case and the one factor that could still surprise investors.

Centene (CNC)

Overview: Centene is a U.S. managed care company that runs Medicaid, Medicare, Affordable Care Act marketplace and commercial health plans, connecting members to primary care doctors, specialists, hospitals and pharmacies, with a focus on under-insured and government sponsored programs.

Operations: Centene generates about US$91.5b from Medicaid, US$38.8b from Medicare, US$41.4b from Commercial plans and US$5.0b from other services and eliminations, with all of its roughly US$178.3b in revenue coming from the United States.

Market Cap: US$33.1b

Centene stands out in the Domestic-Focused U.S. Companies screener because its US$178.3b of revenue is tied entirely to U.S. healthcare programs. Potential tariff driven cost pressures on imports are less central to the story than Medicaid margins, ACA pricing and medical cost trends. The stock is priced on a P/S basis in a way that compares favorably with peers and certain intrinsic value estimates. Q1 2026 results showed revenue of US$49.9b and net income of US$1.5b alongside stronger guidance, which reflects the Medicaid margin recovery and cost actions described in the narrative. At the same time, investors need to consider policy risk, high medical expenses, specialty drug costs and recent insider selling, making the balance between recovery potential and these pressures important to understand.

Centene’s Medicaid recovery and stronger guidance suggest that the story is still evolving, while policy risk and medical costs remain important background factors. See how the 3 key rewards and 1 important warning sign before the next catalyst reshapes expectations

The three stocks covered here are only a starting point, with the full Domestic-Focused U.S. Companies screener surfacing 20 more U.S. focused companies that pair domestic revenue profiles with equally compelling narratives around regulation, margins and capital allocation. Use Simply Wall St to identify and analyze the specific catalysts, risk flags and qualitative narratives that matter most, so you can focus on the highest conviction ideas instead of sifting through hundreds of scattered data points.

Take Control of Your Investment Journey

If Surgery Partners or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Stocks?

Some of the next breakout stories may already be flying under the radar for now, and early movers often set the tone before the crowd catches up, act now.

• Spot potential turnaround stories before sentiment fully catches up by scanning 44 high quality undervalued stocks, curated to highlight companies with solid fundamentals that the broader market may be overlooking.
• Ride accelerating momentum in automation by checking out 31 robotics and automation stocks, a focused set of businesses tied to robots, sensors and software where long term themes meet real operating models.
• Track strong cash generators in the AI space using 63 profitable AI stocks that aren't just burning cash, a filtered group of companies that pair AI exposure with existing profitability instead of ongoing heavy cash burn.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.